Amur Minerals Corporation
CRISM Therapeutics Corporation focuses on drug delivery technology to improve the clinical performance of cancer drugs as treatments for solid tumors. Its lead product, ChemoSeed that can be implanted directly into a tumor or the resection margin following the removal of a tumor, ensuring effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. Its ChemoSeed use… Read more
Amur Minerals Corporation (AMMCF) - Net Assets
Latest net assets as of December 2024: $1.48 Million USD
Based on the latest financial reports, Amur Minerals Corporation (AMMCF) has net assets worth $1.48 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.82 Million) and total liabilities ($341.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.48 Million |
| % of Total Assets | 81.22% |
| Annual Growth Rate | -9.74% |
| 5-Year Change | -95.3% |
| 10-Year Change | -93.44% |
| Growth Volatility | 31.58 |
Amur Minerals Corporation - Net Assets Trend (2006–2024)
This chart illustrates how Amur Minerals Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Amur Minerals Corporation (2006–2024)
The table below shows the annual net assets of Amur Minerals Corporation from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.48 Million | -64.23% |
| 2023-12-31 | $4.12 Million | -85.18% |
| 2022-12-31 | $27.82 Million | -7.61% |
| 2021-12-31 | $30.11 Million | -3.95% |
| 2020-12-31 | $31.35 Million | +13.49% |
| 2019-12-31 | $27.62 Million | +16.95% |
| 2018-12-31 | $23.62 Million | -16.78% |
| 2017-12-31 | $28.38 Million | +10.22% |
| 2016-12-31 | $25.75 Million | +14.60% |
| 2015-12-31 | $22.47 Million | +8.45% |
| 2014-12-31 | $20.72 Million | -30.72% |
| 2013-12-31 | $29.91 Million | +14.15% |
| 2012-12-31 | $26.20 Million | +23.66% |
| 2011-12-31 | $21.19 Million | -1.71% |
| 2010-12-31 | $21.55 Million | +30.48% |
| 2009-12-31 | $16.52 Million | +6.57% |
| 2008-12-31 | $15.50 Million | +10.15% |
| 2007-12-31 | $14.07 Million | +50.82% |
| 2006-12-31 | $9.33 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amur Minerals Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 591288910.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $66.22 Million | 4489.83% |
| Total Equity | $1.48 Million | 100.00% |
Amur Minerals Corporation Competitors by Market Cap
The table below lists competitors of Amur Minerals Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ZIF Immobilien Direkt Schweiz
SW:ZIFIDS
|
$1.37 Million |
|
Armada Berjaya Trans Tbk PT
JK:JAYA
|
$1.37 Million |
|
Voxtur Analytics Corp
OTCQB:VXTRF
|
$1.38 Million |
|
LKL International Bhd
KLSE:0182
|
$1.38 Million |
|
Global Lights Acquisition Corp Rights
NASDAQ:GLACR
|
$1.37 Million |
|
CUMULUS MEDIA INC ADL-01
F:1NM
|
$1.37 Million |
|
CDA S.A. ZY -10
F:6LC
|
$1.37 Million |
|
Hawkmoon Resources Corp
PINK:HWKRF
|
$1.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amur Minerals Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,124,000 to 1,475,000, a change of -2,649,000 (-64.2%).
- Net loss of 607,000 reduced equity.
- Dividend payments of 47,000 reduced retained earnings.
- New share issuances of 102,000 increased equity.
- Other factors decreased equity by 2,097,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-607.00K | -41.15% |
| Dividends Paid | $47.00K | -3.19% |
| Share Issuances | $102.00K | +6.92% |
| Other Changes | $-2.10 Million | -142.17% |
| Total Change | $- | -64.23% |
Book Value vs Market Value Analysis
This analysis compares Amur Minerals Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.09x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.37x to 0.09x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $0.12 | $0.04 | x |
| 2007-12-31 | $0.15 | $0.04 | x |
| 2008-12-31 | $0.13 | $0.04 | x |
| 2009-12-31 | $0.11 | $0.04 | x |
| 2010-12-31 | $0.11 | $0.04 | x |
| 2011-12-31 | $0.08 | $0.04 | x |
| 2012-12-31 | $0.08 | $0.04 | x |
| 2013-12-31 | $0.08 | $0.04 | x |
| 2014-12-31 | $0.05 | $0.04 | x |
| 2015-12-31 | $0.05 | $0.04 | x |
| 2016-12-31 | $0.05 | $0.04 | x |
| 2017-12-31 | $0.05 | $0.04 | x |
| 2018-12-31 | $0.04 | $0.04 | x |
| 2019-12-31 | $0.04 | $0.04 | x |
| 2020-12-31 | $0.03 | $0.04 | x |
| 2021-12-31 | $0.02 | $0.04 | x |
| 2022-12-31 | $0.02 | $0.04 | x |
| 2023-12-31 | $0.47 | $0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amur Minerals Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -41.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2428.00%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.23x
- Recent ROE (-41.15%) is below the historical average (-15.41%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -16.16% | 0.00% | 0.00x | 1.00x | $-2.44 Million |
| 2007 | -14.11% | 0.00% | 0.00x | 1.02x | $-3.39 Million |
| 2008 | -14.85% | 0.00% | 0.00x | 1.03x | $-3.85 Million |
| 2009 | -10.66% | 0.00% | 0.00x | 1.02x | $-3.41 Million |
| 2010 | 1.69% | 0.00% | 0.00x | 1.01x | $-1.79 Million |
| 2011 | -21.75% | 0.00% | 0.00x | 1.00x | $-6.73 Million |
| 2012 | -15.26% | 0.00% | 0.00x | 1.00x | $-6.62 Million |
| 2013 | -12.81% | 0.00% | 0.00x | 1.00x | $-6.82 Million |
| 2014 | -6.57% | 0.00% | 0.00x | 1.02x | $-3.43 Million |
| 2015 | -3.14% | 0.00% | 0.00x | 1.05x | $-2.95 Million |
| 2016 | -22.41% | 0.00% | 0.00x | 1.15x | $-8.35 Million |
| 2017 | -4.07% | 0.00% | 0.00x | 1.03x | $-3.99 Million |
| 2018 | -14.01% | 0.00% | 0.00x | 1.12x | $-5.67 Million |
| 2019 | -8.43% | 0.00% | 0.00x | 1.04x | $-5.09 Million |
| 2020 | -8.51% | 0.00% | 0.00x | 1.03x | $-5.80 Million |
| 2021 | -4.01% | 0.00% | 0.00x | 1.04x | $-4.22 Million |
| 2022 | -10.83% | 0.00% | 0.00x | 1.03x | $-5.79 Million |
| 2023 | -65.66% | 0.00% | 0.00x | 1.16x | $-3.12 Million |
| 2024 | -41.15% | -2428.00% | 0.01x | 1.23x | $-754.50K |
Industry Comparison
This section compares Amur Minerals Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amur Minerals Corporation (AMMCF) | $1.48 Million | -16.16% | 0.23x | $1.37 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |